Chartwell Investment Partners LLC grew its holdings in Roche Holdings AG Basel ADR (OTCMKTS:RHHBY) by 296.0% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 106,004 shares of the company’s stock after acquiring an additional 79,235 shares during the quarter. Chartwell Investment Partners LLC’s holdings in Roche Holdings AG Basel were worth $3,225,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of RHHBY. Cornerstone Investment Partners LLC acquired a new position in shares of Roche Holdings AG Basel in the third quarter valued at $206,000. Mechanics Bank Trust Department acquired a new position in shares of Roche Holdings AG Basel in the third quarter valued at $207,000. Dearborn Partners LLC acquired a new position in shares of Roche Holdings AG Basel in the third quarter valued at $232,000. Gardiner Nancy B acquired a new position in shares of Roche Holdings AG Basel in the third quarter valued at $454,000. Finally, Advisor Partners LLC raised its stake in shares of Roche Holdings AG Basel by 77.1% in the third quarter. Advisor Partners LLC now owns 23,100 shares of the company’s stock valued at $703,000 after purchasing an additional 10,053 shares in the last quarter. 0.31% of the stock is owned by institutional investors.

Several research analysts have issued reports on the company. Cowen reiterated a “buy” rating and set a $34.00 price objective on shares of Roche Holdings AG Basel in a research note on Thursday, July 26th. ValuEngine upgraded Roche Holdings AG Basel from a “sell” rating to a “hold” rating in a research note on Monday, July 30th. Wolfe Research assumed coverage on Roche Holdings AG Basel in a research note on Tuesday, October 23rd. They set a “market perform” rating for the company. Bank of America lowered Roche Holdings AG Basel from a “buy” rating to a “neutral” rating in a research note on Monday, September 10th. Finally, Zacks Investment Research upgraded Roche Holdings AG Basel from a “hold” rating to a “strong-buy” rating and set a $35.00 price objective for the company in a research note on Wednesday, September 12th. Three research analysts have rated the stock with a sell rating, four have issued a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $34.50.

Roche Holdings AG Basel stock opened at $31.40 on Monday. Roche Holdings AG Basel ADR has a 52-week low of $26.30 and a 52-week high of $32.42. The firm has a market cap of $214.00 billion, a price-to-earnings ratio of 16.10, a P/E/G ratio of 1.90 and a beta of 0.53. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.28 and a quick ratio of 0.97.

ILLEGAL ACTIVITY NOTICE: “Chartwell Investment Partners LLC Boosts Stake in Roche Holdings AG Basel ADR (RHHBY)” was originally reported by Daily Political and is the sole property of of Daily Political. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece can be read at https://www.dailypolitical.com/2018/11/19/chartwell-investment-partners-llc-boosts-stake-in-roche-holdings-ag-basel-adr-rhhby.html.

About Roche Holdings AG Basel

Roche Holding AG engages in the diagnostics and pharmaceuticals businesses in Switzerland, Germany, and rest of Europe. It offers pharmaceutical products for anaemia, anticoagulation therapy, bone, cancer, cardiovascular, central nervous system, chlamydia, coagulation, dermatology, diabetes, gonorrhea, gout, hemostasis disorders, hepatitis B and C, HIV/AIDS, HPV, infectious diseases, inflammatory and autoimmune, intensive care medicine, kidney and urogenital tract, leukemia, lipid disorders, liver, lymphoma, metabolic disorders, obesity, occult blood testing, ophthalmology, osteoporosis, pancreatitis, respiratory disorders, rheumatoid arthritis, sepsis, sexually transmitted infections, skin cancer, transplantation, tuberculosis, urinary tract infections, and West Nile virus diseases.

Featured Story: What is a Call Option?

Want to see what other hedge funds are holding RHHBY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Roche Holdings AG Basel ADR (OTCMKTS:RHHBY).

Institutional Ownership by Quarter for Roche Holdings AG Basel (OTCMKTS:RHHBY)

Receive News & Ratings for Roche Holdings AG Basel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche Holdings AG Basel and related companies with MarketBeat.com's FREE daily email newsletter.